Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03678441
Other study ID # 2018-0093
Secondary ID NCI-2018-0189520
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date August 17, 2018
Est. completion date April 30, 2025

Study information

Verified date June 2024
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial studies how well electronic neurocognitive tools work in screening for mental capability in patients who are undergoing liver surgery. Using electronic neurocognitive screening tools may help to better assess mental impairment.


Description:

PRIMARY OBJECTIVES: I. Evaluate feasibility of the electronic batteries, measured by the completion rate and time to completion of the batteries. SECONDARY OBJECTIVES: I. Comparison of the completion rate and time to completion between the written and electronic batteries. II. Comparison of the scoring distribution between the screening tools. EXPLORATORY OBJECTIVES: I. Assess if a history of mental or cognitive illness or ongoing treatment with neuropsychiatric medications impact the ability to complete written and/or electronic neurocognitive screening. OUTLINE: Patients are randomized to 1 of 2 groups. GROUP I: Patients receive the BrainCheck cognitive assessment over 15 minutes followed by the paper and pen cognitive assessment within 2 months prior to surgery and within 2 months after surgery. GROUP II: Patients receive the paper and pen cognitive assessment followed by the BrainCheck cognitive assessment over 15 minutes 2 months prior to surgery and within 2 months after surgery.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 100
Est. completion date April 30, 2025
Est. primary completion date April 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - All English-speaking patients undergoing hepatectomy at main campus University of Texas (UT)-MD Anderson Cancer Center who are cognitively able to provide informed consent in the opinion of the attending physician.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
BrainCheck Cognitive Assessment
Receive BrainCheck cognitive assessment
Procedure:
Cognitive Assessment
Receive pen and paper cognitive assessment

Locations

Country Name City State
United States M D Anderson Cancer Center Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Completion rate of the BrainCheck battery Will be calculated along with a 95% confidence interval (CI). Up to 1 year
Primary Completion rate of the pen and paper assessment Will be calculated along with a 95% CI. Up to 1 year
Primary Average time to complete the BrainCheck battery Will be calculated along with a 95% CI. Up to 1 year
Primary Average time to complete the pen and paper assessment Will be calculated along with a 95% CI. Up to 1 year
Primary Difference in completion rate between the BrainCheck battery and paper and pen assessment Will be calculated along with 95% CIs. Up to 1 year
Primary Difference in time to completion between the BrainCheck battery and the pen and paper assessment Will be calculated along with 95% CIs. Up to 1 year
Primary Difference in score between the BrainCheck battery and the pen and paper assessments Will be calculated along with 95% CIs. Up to 1 year
Primary Sensitivity, specificity, negative predictive value, positive predictive value, and accuracy of the electronic battery compared to the validated St. Louis University Mental Status Examination (SLUMS) Will be calculated along with 95% CIs. Up to 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT03214510 - Thoracic Epidural Analgesia or Four-Quadrant Transversus Abdominus Plane Block in Reducing Pain in Patients Undergoing Liver Surgery Phase 3
Active, not recruiting NCT02156739 - Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions N/A
Recruiting NCT05876182 - Vancomycin in Primary Sclerosing Cholangitis in Italy Phase 2